You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Boehringer Ingelheim
Medtronic
Johnson and Johnson
McKinsey

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Claims for Patent: 5,955,425

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,955,425
Title: Parathyroid hormone analogues for the treatment of osteoporosis
Abstract:This invention describes analogs of human parathyroid hormone which have increased activities in bone restoration, and increased bioavailabilities. The peptides described are derivatives of hPTH-(1-31) which have lactams formed for example, between either Glu.sup.22 and Lys.sup.26 or Lys.sup.26 and Asp.sup.30. In addition, the natural Lys.sup.27 may be substituted by either a Leu or other hydrophobic residues, such as Ile, norleucine, Met, Val, Ala, Trp, or Phe. Typically, these analogs have enhanced abilities to stimulate adenylyl cyclase in rat osteosarcoma cells, and show increased activities in bone restoration, using the ovariectomized rat model. The analogs also show enhanced activities and bioavailabilities, as demonstrated by their hypotensive effects in the rat.
Inventor(s): Morley; Paul (Ottawa, CA), Neugebauer; Witold (Ottawa, CA), Ross; Virginia J. S. (Gloucester, CA), Whitfield; James F. (Ottawa, CA), Willick; Gordon E. (Orleans, CA), Barbier; Jean-Rene (Gatineau, CA)
Assignee: National Research Council of Canada (CA)
Application Number:08/691,647
Patent Claims:1. A human parathyroid hormone hPTH-( 1-31) analogue in which position 27 is Leu, Ile, Nle or Met and which has been cyclized between Glu.sup.22 and Lys.sup.26 to form a lactam.

2. An analogue according to claim 1, having either a free amide C-terminal ending or a free carboxyl C-terminal ending.

3. An analogue according to claim 1, having the SEQ ID NO:3.

4. A composition for administration to a warm-blooded animal comprising a human parathyroid hormone hPTH-(1-31) analogue according to claim 1 in association with a pharmaceutically acceptable carrier or excipient.

5. A method of treating osteoporosis in a warm-blooded animal comprising administering to an animal in need of same a therapeutically effective amount of the human parathyroid hormone hPTH-(1-31) analogue according to claim 1.

6. A human parathyroid hormone hPTH-(1-31) analogue in which position 27 is Leu and which has been cyclized between Glu.sup.22 and Lys.sup.26 to form a lactam.

7. A composition for administration to a warm-blooded animal comprising a human parathyroid hormone hPTH-(1-31) analogue according to claim 6 in association with a pharmaceutically acceptable carrier or excipient.

8. A method of treating osteoporosis in a warm-blooded animal comprising administering to an animal in need of same a therapeutically effective amount of the human parathyroid hormone hPTH-(1-31) analogue according to claim 6.

Details for Patent 5,955,425

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial National Research Council of Canada (CA) 2014-06-20 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial National Research Council of Canada (CA) 2014-06-20 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial National Research Council of Canada (CA) 2014-06-20 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial National Research Council of Canada (CA) 2014-06-20 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 5,955,425

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Colorcon
Harvard Business School
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.